Theravance Biopharma (NASDAQ:TBPH) Stock Crosses Above 50-Day Moving Average – Here’s What Happened

Theravance Biopharma, Inc. (NASDAQ:TBPH)’s share price passed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $16.42 and traded as high as $16.57. Theravance Biopharma shares last traded at $16.49, with a volume of 332,098 shares.

Analyst Ratings Changes

A number of research firms have weighed in on TBPH. Oppenheimer lowered shares of Theravance Biopharma from an “outperform” rating to a “market perform” rating in a research report on Thursday, March 5th. TD Cowen increased their price target on Theravance Biopharma from $13.00 to $15.00 and gave the stock a “hold” rating in a research note on Monday, March 23rd. HC Wainwright boosted their price objective on Theravance Biopharma from $20.00 to $27.00 and gave the company a “buy” rating in a research report on Monday, March 2nd. Zacks Research upgraded Theravance Biopharma from a “hold” rating to a “strong-buy” rating in a research report on Thursday, March 19th. Finally, Wall Street Zen cut Theravance Biopharma from a “buy” rating to a “hold” rating in a report on Saturday, May 16th. Two analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $21.83.

Theravance Biopharma Stock Performance

The stock has a market cap of $850.06 million, a PE ratio of 7.50 and a beta of 0.17. The stock has a fifty day moving average price of $16.42 and a 200 day moving average price of $17.50.

Theravance Biopharma (NASDAQ:TBPH) last announced its earnings results on Tuesday, March 31st. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter. The business had revenue of $17.70 million for the quarter. Theravance Biopharma had a net margin of 104.34% and a return on equity of 18.84%. As a group, equities analysts anticipate that Theravance Biopharma, Inc. will post 1.58 earnings per share for the current fiscal year.

Insider Activity

In other news, SVP Rhonda Farnum sold 31,067 shares of the firm’s stock in a transaction on Monday, March 16th. The stock was sold at an average price of $13.96, for a total transaction of $433,695.32. Following the transaction, the senior vice president owned 232,699 shares in the company, valued at approximately $3,248,478.04. This trade represents a 11.78% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 7.65% of the company’s stock.

Hedge Funds Weigh In On Theravance Biopharma

Hedge funds and other institutional investors have recently modified their holdings of the business. Mirae Asset Global Investments Co. Ltd. raised its stake in Theravance Biopharma by 26.5% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,462 shares of the biopharmaceutical company’s stock worth $46,000 after buying an additional 515 shares in the last quarter. Tower Research Capital LLC TRC raised its position in shares of Theravance Biopharma by 18.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company’s stock worth $55,000 after acquiring an additional 781 shares in the last quarter. Creative Planning raised its position in shares of Theravance Biopharma by 6.7% in the 3rd quarter. Creative Planning now owns 13,450 shares of the biopharmaceutical company’s stock worth $196,000 after acquiring an additional 842 shares in the last quarter. State of Wyoming lifted its stake in shares of Theravance Biopharma by 5.7% during the 2nd quarter. State of Wyoming now owns 18,928 shares of the biopharmaceutical company’s stock worth $209,000 after purchasing an additional 1,019 shares during the last quarter. Finally, The Manufacturers Life Insurance Company lifted its stake in shares of Theravance Biopharma by 6.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 15,747 shares of the biopharmaceutical company’s stock worth $174,000 after purchasing an additional 1,020 shares during the last quarter. 99.10% of the stock is currently owned by institutional investors.

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.